Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNX001 in interstitial cystitis/bladder pain syndrome
NCT05737121Phase 2Recruiting
- Sponsor
- Urigen Pharmaceuticals, Inc.
- Start
- May 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VNX001 in interstitial cystitis (IC), bladder pain syndrome (BPS), sponsored by Urigen Pharmaceuticals, Inc.. Started May 2023; status: recruiting.
02
Drugs
VNX001
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT05737121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737121.